Literature DB >> 30460682

Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenström macroglobulinaemia on ibrutinib.

Matthew P Cheng1,2,3, Amanda E Kusztos1,2, Joshua N Gustine4, Scott L Dryden-Peterson1,2,3, Toni E Dubeau4, Ann E Woolley1,2,3, Sarah P Hammond1,2,3, Lindsey R Baden1,2,3, Steven P Treon3,4, Jorge J Castillo3,4, Nicolas C Issa1,2,3.   

Abstract

Entities:  

Keywords:  zzm321990Pneumocystis jiroveciizzm321990; Waldenstrom's macroglobulinaemia; aspergillosis; ibrutinib

Mesh：

Substances：

Year:  2018        PMID： 30460682     DOI： 10.1111/bjh.15627

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  4 in total

Review 1.  How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.

Authors:  Deborah M Stephens; John C Byrd
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

Review 2.  Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect.

Authors:  Haoran Wang; Hao Guo; Jingyi Yang; Yanyan Liu; Xingchen Liu; Qing Zhang; Keshu Zhou
Journal:  Exp Hematol Oncol       Date:  2022-09-22

3.  Cause-specific mortality in individuals with lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia, 2000-2016.

Authors:  Nicole H Dalal; Graça M Dores; Rochelle E Curtis; Martha S Linet; Lindsay M Morton
Journal:  Br J Haematol       Date:  2020-02-23       Impact factor: 8.615

Review 4.  Invasive Fungal Infections and Targeted Therapies in Hematological Malignancies.

Authors:  Jessica S Little; Zoe F Weiss; Sarah P Hammond
Journal:  J Fungi (Basel)       Date:  2021-12-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.